stockrow
Saturday 7 November 2026
Export MGTX’s income statement to Excel — free account
MeiraGTx Holdings PLC
MGTX Healthcare Biotechnology
MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024.
- Revenue
- +8,608.6%
- EPS
- +466.7%
- Free cash flow
- +13.1%
- Total debt
- +28.6%
Quarter to June 2026, against a year earlier
8.99
0.48
+5.64%
Follow MGTX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
17.78 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.11 | 8.83 | 7.86 | 24.30 | |
P/FCF ratio |
122.01 | 164.35 | 0.00 | 0.00 | |
P/Operating CF |
(32.05) | 39.53 | 13.71 | (54.54) | |
P/B ratio |
5.72 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
5.73 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.00 | 8.55 | 7.66 | 24.18 | |
EV/EBITDA |
6.04 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
87.08 | 82.42 | (13.44) | (5.70) | |
EV/FCF |
117.75 | 159.27 | (12.45) | (5.50) | |
Quick Ratio |
3.23 | 0.51 | 0.69 | 0.17 | |
Current Ratio |
3.76 | 0.55 | 0.75 | 0.22 | |
Net Debt/EBITDA |
(0.17) | 0.58 | (0.54) | 0.08 | |
Debt/Assets |
25.25% | 20.35% | 20.37% | 6.09% | |
Debt/Equity |
0.46 | (0.86) | (8.60) | (0.28) | |
Asset Turnover |
1.34 | 0.34 | 0.32 | 0.11 | |
Operating CF/Net income |
(0.24) | (0.38) | 3.09 | 0.24 | |
Capex/Depreciation |
(0.10) | (0.61) | (0.20) | (0.16) | |
Interest Coverage |
69.66 | (14.33) | 8.67 | (15.02) | |
Research and Development Expense of Revenue |
17.99% | 10,916.04% | 40.88% | 7,934.63% | |
Selling, General and Administrative Expense of Revenue |
3.74% | 3,047.10% | 23.36% | 3,320.98% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.18% | 1,247.10% | 7.43% | 1,451.95% | |
Graham Net Nets |
0.03 | (0.29) | (0.25) | (0.29) | |
Graham Number |
6.35 | 4.88 | 1.52 | 4.88 | |
Earnings Yield |
5.63% | (17.09%) | (17.86%) | (25.64%) | |
Free Cash Flow Yield |
0.82% | 0.61% | (7.83%) | (18.09%) | |
Revenue per Share |
3.52 | 0.00 | 0.94 | 0.01 | |
Operating CF per Share |
(0.42) | 0.22 | 0.58 | (0.15) | |
Capex per Share |
0.00 | (0.02) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.43) | 0.19 | 0.57 | (0.16) | |
Cash per Share |
1.57 | 0.88 | 0.82 | 0.18 | |
Shareholders Equity per Share |
2.36 | (0.71) | (0.07) | (0.50) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.36 | (0.71) | (0.07) | (0.50) | |
Free Cash Flow |
(38.87) | 15.80 | 45.95 | (12.76) | |
Working Capital |
160.25 | (79.93) | (30.79) | (118.75) | |
Capital Expenditures |
(0.33) | (2.01) | (0.68) | (0.55) | |
Net Current Asset Value |
37.68 | (206.58) | (158.46) | (195.85) | |
EV/EBIT |
6.48 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 6.85 | 0.01 | 1.33 | |
Price to Operating Income |
6.71 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.53 | 11.46 | 13.98 | 10.12 | |
Average Payables |
18.63 | 18.47 | 16.83 | 25.52 | |
Average Assets |
297.58 | 234.33 | 257.09 | 244.48 | |
Average Common Equity |
109.37 | (12.52) | 31.02 | 27.59 |
Columns are period end dates · fundamentals updated 25 Oct 2026